EX1 Stock Overview
Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Exopharm Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.011 |
| 52 Week High | AU$0.077 |
| 52 Week Low | AU$0.008 |
| Beta | 1.24 |
| 11 Month Change | 0% |
| 3 Month Change | 10.00% |
| 1 Year Change | n/a |
| 33 Year Change | -98.02% |
| 5 Year Change | -97.68% |
| Change since IPO | -97.66% |
Recent News & Updates
Recent updates
Shareholder Returns
| EX1 | AU Biotechs | AU Market | |
|---|---|---|---|
| 7D | 0% | 3.0% | 1.2% |
| 1Y | n/a | 13.6% | 19.7% |
Return vs Industry: Insufficient data to determine how EX1 performed against the Australian Biotechs industry.
Return vs Market: Insufficient data to determine how EX1 performed against the Australian Market.
Price Volatility
| EX1 volatility | |
|---|---|
| EX1 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 9.8% |
| Market Average Movement | 8.6% |
| 10% most volatile stocks in AU Market | 17.5% |
| 10% least volatile stocks in AU Market | 3.2% |
Stable Share Price: EX1 has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine EX1's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 50 | Ian Dixon | exopharm.com |
Exopharm Limited develops transformative medicines based upon exosomes or extracellular vesicles (EVs) in Australia. The company’s technology includes LOAD technology platform that enables loading of active pharmaceutical ingredient (API) into exosomes; Ligand-based Exosome Affinity Purification (LEAP) technology that solves the critical bottleneck of exosome isolation and purification; MASTER CELL BANK to manufacture clinical-grade engineered exosomes; EVPS technology platform that allows specific molecules to be attached to the surface of exosomes to target them to selected tissues, organs, or cell types; EXORIA, a novel and proprietary dye that tags invisible exosomes to enhance tracking in experimental studies and laboratory analysis; and FORMULATION H to enable the stable storage and transport of exosome medicines. Exopharm Limited has research collaboration agreements with Astellas Institute for Regenerative Medicine.
Exopharm Limited Fundamentals Summary
| EX1 fundamental statistics | |
|---|---|
| Market cap | AU$4.83m |
| Earnings (TTM) | -AU$7.13m |
| Revenue (TTM) | AU$3.39m |
1.4x
P/S Ratio-0.7x
P/E RatioIs EX1 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EX1 income statement (TTM) | |
|---|---|
| Revenue | AU$3.39m |
| Cost of Revenue | AU$3.36m |
| Gross Profit | AU$28.17k |
| Other Expenses | AU$7.16m |
| Earnings | -AU$7.13m |
Last Reported Earnings
Jun 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.016 |
| Gross Margin | 0.83% |
| Net Profit Margin | -210.14% |
| Debt/Equity Ratio | 37.2% |
How did EX1 perform over the long term?
See historical performance and comparison